Meeting
2022 ASCO Annual Meeting
Efficacy and safety of dostarlimab in patients (pts) with mismatch repair deficient (dMMR) solid tumors: Analysis of 2 cohorts in the GARNET study.
Presenter
Thierry Andre, MD
Sorbonne University, Saint-Antoine Hospital, AP-HP
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Videos & Slides Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics—Immunotherapy
Sub Track
PD1/PD-L1 Inhibitor Monotherapy
Clinical Trial Registration Number
NCT02715284
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 2587)
DOI
10.1200/JCO.2022.40.16_suppl.2587
Abstract #
2587
Poster Bd #
242
Abstract Disclosures
Similar Videos & Slides
Videos & Slides
2021 Gastrointestinal Cancers Symposium
Safety and efficacy of anti–PD-1 antibody dostarlimab in patients (pts) with mismatch repair-deficient (dMMR) solid cancers: Results from GARNET study.
Speaker: Thierry Andre, MD
Videos & Slides
2022 ASCO Gastrointestinal Cancers Symposium
Antitumor activity and safety of dostarlimab monotherapy in patients with mismatch repair deficient non-endometrial solid tumors: A post-hoc subgroup analysis of patients with colorectal cancer.
Speaker: Thierry Andre, MD
Videos & Slides
2024 ASCO Annual Meeting
A phase 1/2 study of REGN7075 in combination with cemiplimab (cemi) in patients (pts) with advanced solid tumors: Efficacy and safety results.
Speaker: Neil Howard Segal, MD, PhD
Videos & Slides
2024 ASCO Annual Meeting
Preliminary results of phase I/II study to evaluate safety and efficacy of combination pucotenlimab with epidermal growth factor receptor-ADC (EGFR-ADC) MRG003 in patients with EGFR positive solid tumors.
Speaker: Dan-yun Ruan, MD